Market Cap : 1.37 B | Enterprise Value : 1.12 B | P/E (TTM) : | P/B : 4.54 |
---|
NAS:TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Travere Therapeutics's Accounts Receivable for the three months ended in Sep. 2020 was $15.0 Mil. Travere Therapeutics's Revenue for the three months ended in Sep. 2020 was $51.1 Mil. Hence, Travere Therapeutics's days sales outstanding for the three months ended in Sep. 2020 was 26.81.
During the past 9 years, Travere Therapeutics's highest Days Sales Outstanding was 103.02. The lowest was 28.14. And the median was 41.55.
Travere Therapeutics's days sales outstanding declined from Sep. 2019 (34.51) to Sep. 2020 (26.81).
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Travere Therapeutics's Days Sales Outstanding falls into.
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Travere Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2019 is calculated as
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 18.048 | / | 175.338 | * | 365 | |
= | 37.57 |
Travere Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2020 is calculated as:
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 15.025 | / | 51.139 | * | 365 / 4 | |
= | 26.81 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
No Headline